ZA200707486B - Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease - Google Patents

Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease

Info

Publication number
ZA200707486B
ZA200707486B ZA200707486A ZA200707486A ZA200707486B ZA 200707486 B ZA200707486 B ZA 200707486B ZA 200707486 A ZA200707486 A ZA 200707486A ZA 200707486 A ZA200707486 A ZA 200707486A ZA 200707486 B ZA200707486 B ZA 200707486B
Authority
ZA
South Africa
Prior art keywords
disease
parkinson
treatment
cyclohexanedione
nitro
Prior art date
Application number
ZA200707486A
Other languages
English (en)
Inventor
Doe John Ernest
Sturgess Nicholas Crispinian
Travis Kim Zachary
Original Assignee
Syngenta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngenta Ltd filed Critical Syngenta Ltd
Publication of ZA200707486B publication Critical patent/ZA200707486B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA200707486A 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease ZA200707486B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method

Publications (1)

Publication Number Publication Date
ZA200707486B true ZA200707486B (en) 2009-02-25

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707486A ZA200707486B (en) 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease

Country Status (17)

Country Link
US (1) US20090326072A1 (https=)
EP (1) EP1853241B1 (https=)
JP (1) JP2008531665A (https=)
CN (1) CN101163466B (https=)
AT (1) ATE524171T1 (https=)
AU (1) AU2006217650B2 (https=)
BR (1) BRPI0609177A2 (https=)
CA (1) CA2598517A1 (https=)
DK (1) DK1853241T3 (https=)
ES (1) ES2374761T3 (https=)
GB (1) GB0504103D0 (https=)
IL (1) IL185410A0 (https=)
MX (1) MX2007010480A (https=)
PT (1) PT1853241E (https=)
RU (1) RU2420272C2 (https=)
WO (1) WO2006090177A1 (https=)
ZA (1) ZA200707486B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010054273A1 (en) * 2008-11-06 2010-05-14 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
RS54632B1 (sr) 2011-06-23 2016-08-31 Swedish Orphan Biovitrum International Ab Tečna farmaceutska kompozicija koja sadrži nitizinon
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーTakeda GmbH 糖尿病性腎症を治療するためのpde4阻害剤
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof
TW202543611A (zh) * 2024-03-27 2025-11-16 美商費斯製藥有限公司 Hpd抑制劑組成物及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones
JP3130935B2 (ja) * 1991-06-24 2001-01-31 ゼネカ リミテッド 医薬組成物
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
WO2005007096A2 (en) * 2003-07-11 2005-01-27 Merck & Co., Inc. Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
NZ574153A (en) * 2006-08-18 2011-12-22 Syngenta Ltd Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
WO2010054273A1 (en) * 2008-11-06 2010-05-14 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders

Also Published As

Publication number Publication date
CN101163466A (zh) 2008-04-16
PT1853241E (pt) 2012-01-11
DK1853241T3 (da) 2012-01-16
RU2420272C2 (ru) 2011-06-10
GB0504103D0 (en) 2005-04-06
HK1110211A1 (en) 2008-07-11
AU2006217650A1 (en) 2006-08-31
AU2006217650B2 (en) 2011-06-09
ES2374761T3 (es) 2012-02-21
CA2598517A1 (en) 2006-08-31
IL185410A0 (en) 2008-08-07
MX2007010480A (es) 2008-02-07
RU2007131934A (ru) 2009-02-27
JP2008531665A (ja) 2008-08-14
US20090326072A1 (en) 2009-12-31
ATE524171T1 (de) 2011-09-15
EP1853241A1 (en) 2007-11-14
WO2006090177A1 (en) 2006-08-31
BRPI0609177A2 (pt) 2010-02-23
EP1853241B1 (en) 2011-09-14
CN101163466B (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200728307A (en) Novel spirochromanone derivatives
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MY151295A (en) Pyrimidyl indoline compound
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2009067493A3 (en) 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
PT1778837E (pt) Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4
TW200716547A (en) Piperidin-4-yl-amide derivatives
GB0516168D0 (en) Pharmaceutical compounds
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
DE602007008947D1 (en) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease
HK1164058A (en) Specific diarylhydantoin and diarylthiohydantoin compounds